بدائل البحث:
increase decrease » increased release (توسيع البحث), increased crash (توسيع البحث)
greater decrease » greatest decrease (توسيع البحث), greater increase (توسيع البحث), greater disease (توسيع البحث)
trend decrease » teer decrease (توسيع البحث)
increase decrease » increased release (توسيع البحث), increased crash (توسيع البحث)
greater decrease » greatest decrease (توسيع البحث), greater increase (توسيع البحث), greater disease (توسيع البحث)
trend decrease » teer decrease (توسيع البحث)
-
1781
-
1782
-
1783
Summary of study eligibility criteria.
منشور في 2025"…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …"
-
1784
Summary of study participation and feasibility.
منشور في 2025"…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …"
-
1785
Sociodemographic and economic factors of study subjects, Ethiopia, EDHS 2005–2016 (N = 29,525).
منشور في 2024الموضوعات: -
1786
-
1787
-
1788
Frequency distribution of SOLEC at baseline and follow-ups in WAD grade 2 and WAD grade 3.
منشور في 2024الموضوعات: -
1789
-
1790
-
1791
Baseline descriptive characteristics of trial participants (n = 140) with and without dizziness.
منشور في 2024الموضوعات: -
1792
Frequency distribution of SOLEC at baseline and follow-ups in the NSEIT and NSE groups.
منشور في 2024الموضوعات: -
1793
-
1794
Baseline descriptive characteristics of trial participants with dizziness, by treatment group.
منشور في 2024الموضوعات: -
1795
-
1796
-
1797
-
1798
-
1799
-
1800